Access

News and Views


Nature Medicine 8, 20 - 21 (2002)
doi:10.1038/nm0102-20

Shedding growth factors in cardiac hypertrophy

James K. Liao1

  1. Cardiovascular Division, Department of Medicine Brigham & Women's Hospital and Harvard Medical School Cambridge, Massachusetts, USA
    e-mail: jliao@rics.bwh.harvard.edu


The finding that cleavage and shedding of the membrane-bound heparin-binding epidermal growth factor by metalloproteases contribute to the hypertrophic process offers new insights for the treatment of cardiac hypertrophy and progression to heart failure. (pages 35–40)


Cardiac hypertrophy is an adaptive physiological response to increases in blood pressure that preserves myocardial wall stress, chamber size and contractile function. Despite these initial advantages, cardiac hypertrophy is also an independent risk factor for cardiovascular disease and, if left untreated, it frequently progresses to heart failure1.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

REVIEWS
Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission
Oncogene Reviews (30 Mar 2001)
G-proteins in growth and apoptosis: lessons from the heart
Oncogene Reviews (30 Mar 2001)
 See all 3 matches for Reviews

RESEARCH
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
Nature Medicine Article (01 Jan 2002)
Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling
The EMBO Journal Article (01 Jun 2003)
TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells
The EMBO Journal Article (15 May 2003)
 See all 4 matches for Research